The first patient dosed with VX-880 demonstrated restoration of insulin production and achieved C-peptide of 560 pmol/L in response to Mixed Meal Tolerance Test (MMTT) at Day 90 visit
Mahler brings more than 20 years of leadership experience spanning cell therapy, biopharmaceutical development, manufacturing, and global business management
Exclusive partnership introduces globally benchmarked stem cell processing platform aimed at improving stem cell recovery, quality, and long-term therapeutic potential
The safety profile was described as manageable, though not without notable toxicities
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
SFDA nod marks company’s strategic entry into high-value specialty oncology injectables as it targets expanding stem cell transplant and haemato-oncology market in the GCC region
The move targets long-standing bottlenecks in MSC science, including cell-to-cell variability, immunocompatibility concerns, and inefficient manufacturing workflows
As per GlobalData, CARsgen’s satri-cel could mark a major breakthrough in solid tumor treatment as competition intensifies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
